Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03.

Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, Donnelly BJ, Venner PM, Perez CA, Murray KJ, Doggett RS, True LD.

J Clin Oncol. 1998 Nov;16(11):3576-83.

PMID:
9817278
2.

RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.

Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):665-72.

PMID:
14529770
4.
5.

Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.

Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, True L, Shipley W.

J Clin Oncol. 1996 Jan;14(1):119-26.

PMID:
8558186
6.

Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study.

Fellin G, Graffer U, Bolner A, Ambrosini G, Caffo O, Luciani L.

Br J Urol. 1997 Jul;80(1):44-9.

PMID:
9240179
7.

Bladder preservation by combined modality therapy for invasive bladder cancer.

Kachnic LA, Kaufman DS, Heney NM, Althausen AF, Griffin PP, Zietman AL, Shipley WU.

J Clin Oncol. 1997 Mar;15(3):1022-9.

PMID:
9060542
9.

Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.

George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, Serment G, Salem N.

Urology. 2004 Sep;64(3):488-93. Review.

PMID:
15351577
10.

[Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].

Zapatero A, Pinar B, Arellano R, López M, Marín A, Jiménez U, Pérez Torrubia A.

Arch Esp Urol. 1997 Jun;50(5):448-54; discussion 454-6. Spanish.

PMID:
9382586
11.

Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy.

Prout GR Jr, Shipley WU, Kaufman DS, Heney NM, Griffin PP, Althausen AF, Bassil B, Nocks BN, Parkhurst EC, Young HH 2nd.

J Urol. 1990 Nov;144(5):1128-34; discussion 1134-6.

PMID:
2122007
12.

Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.

Kitamura H, Tsukamoto T, Shibata T, Masumori N, Fujimoto H, Hirao Y, Fujimoto K, Kitamura Y, Tomita Y, Tobisu K, Niwakawa M, Naito S, Eto M, Kakehi Y; Urologic Oncology Study Group of the Japan Clinical Oncology Group.

Ann Oncol. 2014 Jun;25(6):1192-8. doi: 10.1093/annonc/mdu126. Epub 2014 Mar 24.

PMID:
24669010
14.

Can patient selection for bladder preservation be based on response to chemotherapy?

Sternberg CN, Pansadoro V, Calabrò F, Schnetzer S, Giannarelli D, Emiliozzi P, De Paula F, Scarpone P, De Carli P, Pizzo M, Platania A, Amini M.

Cancer. 2003 Apr 1;97(7):1644-52.

15.

Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy.

Fung CY, Shipley WU, Young RH, Griffin PP, Convery KM, Kaufman DS, Althausen AF, Heney NM, Prout GR Jr.

J Clin Oncol. 1991 Sep;9(9):1533-42.

PMID:
1875217
16.

Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.

Higano CS, Tangen CM, Sakr WA, Faulkner J, Rivkin SE, Meyers FJ, Hussain M, Baker LH, Russell KJ, Crawford ED; Southwest Oncology Group Trial 8733.

Cancer. 2008 May 15;112(10):2181-7. doi: 10.1002/cncr.23420.

17.

[Conservative treatment of locally advanced bladder carcinoma: neoadjuvant chemotherapy, TUR and radiotherapy. Results in 40 patients].

Serretta V, Vasile P, Falletta V, Piazza F, Pavone C, Pavone-Macaluso M.

Arch Ital Urol Androl. 1998 Jun;70(3 Suppl):37-40. Italian.

PMID:
9707769
18.

Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: a phase I/II Southwestern Oncology Group study.

Einstein AB Jr, Wolf M, Halliday KR, Miller GJ, Hafermann M, Lowe BA, Meyers FJ, Leimert JT, Crawford ED.

Urology. 1996 May;47(5):652-7.

PMID:
8650861
19.

The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.

Matsui Y, Nishiyama H, Watanabe J, Teramukai S, Ono Y, Ohshima S, Fujimoto K, Hirao Y, Fukushima M, Ogawa O.

Int J Clin Oncol. 2005 Apr;10(2):133-8.

PMID:
15864700
20.

Supplemental Content

Support Center